Abstract Number: 1922 • ACR Convergence 2023
Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol
Background/Purpose: Hidradenitis suppurativa (HS) is a multifactorial auto-inflammatory disorder with a prevalence of 1% in North American and European populations. HS may be associated with…Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…Abstract Number: 1963 • ACR Convergence 2023
Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis
Background/Purpose: Dysregulation of the interferon (IFN) pathway plays a major role in the pathophysiology of autoimmune myositis. Upregulation of type 1 IFN stimulated genes (an…Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…Abstract Number: 0937 • ACR Convergence 2023
IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice
Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…Abstract Number: 2044 • ACR Convergence 2023
Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Background/Purpose: IFN-mediated diseases are mendelian innate immunodysregulatory disorders that present early in life with fevers, sterile organ inflammation, and a high type-I IFN-response gene signature…Abstract Number: 0574 • ACR Convergence 2023
Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE
Background/Purpose: Aberrant activation of type I IFN, and subsequent adverse clinical implications, have been widely discussed in relation to SLE. With the lack of consistent…Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…Abstract Number: 0598 • ACR Convergence 2023
Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study
Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…Abstract Number: 1240 • ACR Convergence 2023
Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash
Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…Abstract Number: 2329 • ACR Convergence 2023
AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo
Background/Purpose: Inflammatory stimuli induce transcription factors (TFs) such as NF-kB and interferon regulatory factors (IRFs). TFs are transported from cytosol to nucleus to activate genes…Abstract Number: 0608 • ACR Convergence 2023
Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…Abstract Number: 1271 • ACR Convergence 2023
Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)
Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 15
- Next Page »